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Abstract
Heparanase expression has been linked to increased
tumor invasion, metastasis, and angiogenesis and
with poor prognosis. The aim of the study was to
monitor the effect of heparanase expression on lymph
node metastasis, in heparanase-overexpressing sub-
cutaneous Eb mouse T-lymphoma tumors, and their
draining lymph node. Dynamic contrast-enhanced
magnetic resonance imaging (MRI) using biotin-BSA-
GdDTPA-FAM/ROX was applied for analysis of blood
volume, vascular permeability, and interstitial convec-
tion, and for detection of very early stages of such
metastatic dissemination. Eb tumors increased extra-
vasation, interstitial convection, and lymphatic drain of
the contrast material. Interstitial flow directions were
mapped by showing radial outflow interrupted in some
tumors by directional flow toward the popliteal lymph
node. Heparanase expression significantly increased
contrast enhancement of the popliteal lymph node but
not of the primary tumor. Changes in MR contrast
enhancement preceded the formation of pathologically
detectable metastases, and were detectable when only
a few enhanced green fluorescent protein (EGFP)–
expressing Eb cells were found near and within
the nodes. These results demonstrate very early,
heparanase-dependent vascular changes in lymph
nodes that were visible by MRI following administra-
tion of biotin-BSA-GdDTPA-FAM/ROX, and can be used
for studying the initial stages of lymph node infiltration.
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Introduction
Heparanase, an enzyme that degrades heparan sulfate
proteoglycans in the extracellular matrix (ECM), was previ-
ously implicated in hematogenousmetastasis and poor prog-
nosis in a few types of cancer [1–5]. Eb mouse T-lymphoma
cells are nonmetastatic, forming a defined tumor mass at
the site of inoculation in nude mice. A previous study reported
that Eb cells transfected to express the secreted form of
heparanase acquired higher invasiveness in vitro, in Matrigel
invasion assay, and in vivo, reflected by rapid and massive liver
colonization [2]. The aims of the study reported here were to
evaluate the role of heparanase in metastatic spread to senti-
nel lymph nodes, and to determine the feasibility to detect by
magnetic resonance imaging (MRI) early changes associated
with lymph node dissemination of metastatic tumor cells.
Early detection of dissemination of tumor cells to sentinel
lymph nodes is important for evaluation of tumor progression.
In particular, determination of node involvement is required for
novel intervention strategies aimed at suppressing peritumor
lymphangiogenesis and lymphatic drain [6–8]. A number of
imaging modalities were used for the detection of lymph
node involvement including lymphoscintigraphy [9] and MRI
[10–14]. Ultrasmall superparamagnetic iron oxide particles
(USPIO) and gadolinium-labeled molecules were used for
intravenous and interstitial MR lymphography, and revealed
changes in lymph nodes when those exhibited substantial
tumor involvement. Long-circulating USPIO accumulate in
lymph nodes by direct passage through capillaries, or by exit
from the circulation to the interstitium and drain through lym-
phatic vessels [15,16]. Within 24 hours from intravenous injec-
tion, endocytosis of USPIO by macrophages in the nodes
causes a decrease in signal intensity due to magnetic suscep-
tibility and T2-shortening effects. Recently, USPIO showed
high sensitivity and specificity for detection of lymph node
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metastases in a clinical trial [16]. Tumor involvement is
detected by exclusion of the contrast material from tumor-
colonized lymph nodes. Thus, this method does not measure
the drain from the primary tumor toward the lymph node, and
is also not sensitive to early stages of metastasis when the
tumor burden in the node is very low.
Interstitial MR lymphography was done using contrast
materials that vary in size and nature [10–12,17]. Recently,
gadolinium-labeled dendrimers of various generation and
core type were used for visualizing lymphatic vessels and
lymph nodes in normal mice and in pathologies such as
lymphangitis, lymphoma, and lymph node metastases [18].
Lymphangiography by this approach cannot map the flux of
peritumor interstitial convection because the pattern of lym-
phatic drain that is detected is dictated by the site of
administration of the contrast agent.
Albumin-GdDTPA, a prototype of macromolecular MR
contrast materials [19], was first reported in 1987 [20].
Although Albumin-GdDTPA is not a candidate for clinical
application due to slow and incomplete clearance and po-
tential induction of immunologic toxicity [19], it was used
extensively in many experimental tumor models [21–24].
Blood volume and microvascular permeability were quanti-
tatively estimated using kinetic models and correlated with
histologic capillary density [22,25,26]. In addition, the mac-
romolecular contrast material was biotinylated to allow his-
tologic detection of its distribution [27].
We used similar contrast materials, albumin triply labeled
with biotin, fluorescent tag, and GdDTPA (biotin-BSA-
GdDTPA-FAM/ROX), to study the microvasculature of nor-
mal and malignant tissues [28–33]. The application of this
contrast material was further extended by demonstrating
interstitial convection and lymphatic uptake of the extrava-
sated contrast material, which was detectable by MRI and
ex vivo confocal microscopy [28,29].
We show here that MRI and histology revealed elevated
vascular permeability in lymphoma tumors as well as in their
draining lymph nodes. Interstitial flow maps showed direc-
tional drain of the contrast agent from the primary tumor,
whereas contrast enhancement in the lymph nodes occurred
before the formation of liver metastases and preceded
pathologically detectable lymphatic metastasis. Heparanase
expression induced significant increases in MR contrast
enhancement of the popliteal lymph node, suggesting that
heparanase may support secondary angiogenesis during
tumor cell colonization of the nodes. Hence, a single admin-
istration of biotin-BSA-GdDTPA-FAM/ROX provided a tool
for evaluation of the very early stages of lymphatic-mediated
tumor metastasis.
Materials and Methods
Contrast Materials
Biotin-BSA-GdDTPA was derived from bovine serum
albumin (BSA) labeled with biotin and GdDTPA (biotin-
BSA-GdDTPA; approximately 82 kDa; relaxivity of
192 mM1 s1 at 4.7 T) [30]. BSA and biotin-BSA-GdDTPA
were further labeled with rhodamine (ROX) or fluorescein
(FAM) derivatives (Molecular Probes, Inc., Eugene, OR)
[30]. During the MRI session, biotin-BSA-GdDTPA was
injected intravenously (10 mg/mouse, out of which 2.5 mg
was also fluorescently labeled). Immediately after imag-
ing, BSA labeled with the other fluorescent marker (3 mg/
mouse) was administered intravenously, the mice were
sacrificed within 3 minutes, and tissues were retrieved for
histologic analysis.
Cell Lines and Tumor Models
Eb mouse T-lymphoma cells transfected with chicken
heparanase (Eb-chk-hpa) or mock-transfected (Eb-mock)
were cultured as reported [2,34]. Stably transfected cells
were maintained in selection medium containing neomycin
(400 mg/ml; Gibco BRL, Life Technologies, Paisley, Scot-
land, UK). Heparanase activity was verified as reported
previously [35,36].
Heparanase and mock-transfected Eb cells (3  105)
were further stably transfected with enhanced green fluo-
rescent protein (EGFP; pIRES-EGFP-Puro plasmid; 2 mg)
using the FuGene 6 reagent, according to manufacturer
procedure (Roche Diagnostics Corporation, Mannheim, Ger-
many). Stable Eb cell populations expressing various EGFP
levels were selected in the presence of 2.5 mg/ml puromycin
(Sigma Chemical Co., St. Louis, MO).
All animal experiments were approved by the Weizmann
Institutional Animal Care and Use Committee. CD1-nude
mice (female; 6–10 weeks old; body weight f30 g) were
inoculated with tumor cells (0.5  106 cells/mouse) in the
subcutaneous/intradermal tissue of the hind limb.
In Vivo MRI Experiments
Mice were studied by MRI 8 days after inoculating the
tumor cells (Eb-chk-hpa, n = 19; Eb-mock, n = 10). Mice
were anesthesized by intraperitoneal injection of 75 mg/kg
ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and
3 mg/kg xylazine (Vitamed Ltd., Bat-Yam, Israel) and half of
the initial dose was added subcutaneously, 20 minutes
later, in order to prolong the anesthesia. The tail vein was
catheterized with home-built catheters fitted with heparin-
washed needle. MRI experiments were performed at 4.7 T
on a horizontal Bruker Biospec spectrometer (Karlsruhe,
Germany) using a 7-cm resonator for excitation and an
actively decoupled 1.5-cm surface coil for detection. Three-
dimensional gradient echo (3D-GE) images of the tumor-
bearing limb were acquired before and sequentially for
55 minutes after intravenous injection of biotin-BSA-
GdDTPA. The three-dimensional field of view (FOV) of the
image covered the entire hind limb up to the pelvis, contain-
ing the tumor and the popliteal lymph node.
Experimental parameters: precontrast flip angles 5j,
15j, 30j, 50j, 70j; postcontrast flip angle 15j; TR 10 milli-
seconds; TE 3.6 milliseconds; two averages; spectral
width 50,000 Hz; matrix 128  128  64; acquisition time
163 seconds; frequency encoding direction head– foot,
FOV 20  20  20 mm; slice thickness 312 mm; in-plane
resolution 156  156 mm.
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Analysis of Dynamic MR Data
The 3D datasets were zero-filled to 128  128  128.
Maximal intensity projections (MIPs) were generated for
each postcontrast time point, after subtraction of the precon-
trast dataset (Figure 1). Presentation of 3D images as MIP
highlights regions with pronounced contrast enhancement.
The diameter of intratumor vessels and normal capillaries is
smaller than the image resolution (~150 mm) and, due to
partial volume averaging, the contribution of these vessels is
less pronounced relative to the larger vessels observed in
the MIPs early after injection of contrast material. However,
vessel density and regions of permeable vessels were
extracted from the 3D datasets by pharmacokinetic analysis
of the accumulation of contrast material. Pixel-by-pixel anal-
ysis was done on a personal computer using MATLAB
software (MathWorks, Inc., Natick, MA) to generate concen-
tration maps of biotin-BSA-GdDTPA for selected slices of the
GE-3D datasets as described [33]. Precontrast longitudinal
relaxation rate (R1pre) maps were derived from the variable
flip angle data by nonlinear best fit to Eq. (1):
I ¼ M0sinað1 e
TRR1preÞ
1 cosaeTRR1pre ð1Þ
where I is signal intensity as a function of pulse flip angle
a, TR is the repetition time (10 milliseconds), and the pre-
exponent term M0 includes the spin density and the T2
relaxation, which are assumed to be constant.
Postcontrast R1 values (R1post) were calculated from
precontrast and postcontrast 3D-GE signal intensities
(Eq. (2)):
Ipre
Ipost
¼ M0sinað1 e
TRR1preÞ=ð1 cosaeTRR1preÞ
M0sinað1 eTRR1post Þ=ð1 cosaeTRR1post Þ
Finally, concentration maps were calculated based on the
relaxivityR of biotin-BSA-Gd-DTPA [192mM 1 s 1; Eq. (3)]:
½biotin BSAGdDTPA ¼ 1
R
ðR1post  R1preÞ ð3Þ
Blood concentration was evaluated from early concentra-
tion maps of slices containing the femoral vein. The change
in concentration postcontrast was used for the derivation of
three parameter maps [28] (Figure 2):
1. The blood volume fraction (fBV): the ratio between the
extrapolated concentration of biotin-BSA-GdDTPA at the
time of administration and the concentration in the blood.
This parameter indicates (micro)vascular density.
2. The permeability surface area product (PS; min 1): the
initial rate of contrast accumulation (first 15 minutes
postcontrast) normalized to initial blood concentration
(1.5 minutes postcontrast). PS reflects the leak of
macromolecules out of blood vessels and their accumu-
lation in the tissues.
3. Macromolecular convection (Time2Max, min): the time at
which the rate of accumulation of biotin-BSA-GdDTPA
was maximal. Postcontrast time was divided into six
semioverlapping intervals of six scans (16 minutes and
18 seconds each) and, for each interval, the linear slope
was derived.
Numeric values of fBV and PS were calculated frommean
concentration values at selected regions of interest in all
relevant slices (concentration maps) containing the tumor or
the popliteal lymph node. For presentation of parametric
maps, the stacks of fBV and PS maps (generated for slices
of interest) were projected to show the mean value in each
pixel in the axial plain. Time2Max maps were projected to
show the earliest time of maximal rate of accumulation in
each pixel. Before projecting, linear slopes with r < 0.7 (for
node slices) or r < 0.9 (for tumor slices) were discarded. Note
that no threshold was used for derivation of numeric values
from regions of interest, as listed above.
Figure 1. Dynamic contrast-enhanced MRI. Tumor-bearing mice were studied before and after intravenous injection of macromolecular contrast material (Biotin-
BSA-GdDTPA) in the tail vein. Dynamic 3D imaging included follow-up of contrast enhancement for 1 hour postcontrast (20 time points). (A) Tumor inoculation site
(yellow spot) and the FOV of the image (framed box) are indicated. (B–D) Maximal intensity projections of selected 3D images of Eb-chk-hpa tumor-bearing mouse
(1.5, 15, and 55 minutes postcontrast). (E and F) Overlay of the maximal intensity projections. Early time point in red and later time points in green. Arrows indicate
the popliteal lymph node; arrowheads point the tumor. Scale bar = 5 mm.
(2)
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In addition, maps of flow direction were generated. The
signal intensity of the first time point (showing only vascular
enhancement) was subtracted from all subsequent time
points (showing vascular and extravascular signal), so as
to eliminate the contribution of blood vessels to the MIPs.
After subtraction, MIPs were generated for those image
slices including the tumor. Flow vectors were calculated from
the local signal intensity gradient (DSI and direction) for each
pixel in the MIP (calculated in 3  3 matrix; for pixels with
SNR >12 times mean SD of the noise). DSI was summed in
each time interval (16 minutes, 18 seconds each) such that
random fluctuations were largely averaged. Finally, the
Figure 2. Blood volume, vascular permeability, and interstitial flow of primary Eb tumors and draining lymph nodes. (A and B) Typical concentration curves for
tumor region and popliteal lymph node of mice inoculated with Eb-chk-hpa (white circles) or Eb-mock (gray circles) tumors and for normal tissue away from the
tumor (black dots). Linear fit of the first 15 minutes (trend lines) was used for derivation of blood volume fraction (fBV; tissue concentration at time zero divided by
blood concentration) and permeability surface area product (PS; the slope of concentration curve normalized to blood concentration). (C) Contrast accumulation
curves of different tumor and peritumor regions. Color-coded semioverlapping time intervals of delayed accumulation of contrast material used for mapping
interstitial flow (Time2Max). (D and E) Representative overlay MIPs (1.5 minutes in red; 55 minutes in green), fBV, PS, and Time2Max map 8 days after inoculation
of tumors. Tumor slices, large frame; popliteal slices, small frame. Arrows indicate the popliteal lymph node. Scale bar = 5 mm. (F and G) fBV and PS values were
calculated for each mice by linear regression, after averaging the concentration of contrast material in the selected regions of interest (tumor or popliteal lymph
node) from all relevant concentration maps. Values (mean ± SD) for Eb-chk-hpa (white bars; n = 19) and Eb-mock (gray bars; n = 10). *Indicates two-tailed
unpaired t test (P = .02).
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corresponding pixel in the flow map was assigned the angle
(direction of intensity gradient in an arbitrary axis system,
encoded by color) obtained at the time interval with the
highest-magnitude change (see Results section for more
details and graphic representations of flow analysis).
Confocal Microscopy and Histology
Tumors, lymph nodes (popliteal and subiliac), and livers
were excised for histology on day 8 from most mice studied
by MRI and from mice with EGFP-labeled Eb tumors (Eb-
chk-hpa, n = 3; Eb-mock, n = 2). Additional tissue samples
were retrieved from mice with EGFP-labeled Eb tumors on
day 11 (Eb-chk-hpa, n = 2; Eb-mock, n = 3). Liver metastasis
were verified 11 days after inoculation of twice the cell dose
(1  106; Eb-chk-hpa, n = 4) in the lower back (instead of the
hind limb) as previously described [2].
Skin and subcutaneous tumors were first scanned by
confocal microscope (Eclipse TE300; Nikon, Kanagawa,
Japan) equipped with laser scanning system (Radiance
2000; Bio-Rad, Hemel Hempstead, UK) [28,29]. Tissue
samples were fixed in Carnoy’s solution (6:3:1 ethanol/
chloroform/acetic acid) embedded in paraffin and sectioned
at 4 mm. Sections were deparaffinized (xylene), rehydrated
(100%, 95%, 70% ethanol, and PBS; 5 minutes each),
blocked (2% BSA in PBS, 1 hour), and incubated with
rabbit polyclonal anti-GFP antibody (1 hour; Abcam Ltd.,
Cambridge, UK). Alkaline phosphatase–conjugated goat-
antirabbit IgG (Jackson ImmunoResearch Laboratories,
Inc., West Baltimore Pike West Grove, PA) was used as
secondary antibody, with Fast Red (Sigma Chemical Co.) as
a substrate for color reaction. Mayer’s hematoxylin solution
(Sigma Chemical Co.) was used for nuclei counterstaining.
Fluorescent contrast materials remained visible after
processing for histology. Therefore, slides were only coun-
terstained (Hoechst nuclear staining; 1:1000 in PBS for
2 minutes; Molecular Probes, Inc., Eugene, OR) and sealed
with antifade reagent (Molecular Probes, Inc.). When MR
contrast material was used without a fluorescent label, it was
visualized using avidin FITC (Sigma Chemical Co.) or avidin
Texas red (Molecular Probes, Inc.).
Fluorescent probes were viewed by Optiphot2 micro-
scope (Nikon) and photographed by CCD camera (DVC
Company, Austin, TX), and EGFP staining was examined
using Eclipse E800 microscope with Digital Camera DXM
1200 (Nikon).
Results
Vascular Hyperpermeability in Primary Eb Tumors
and Draining Lymph Nodes
Eb cells were inoculated in the hind limb, allowing selec-
tion of a small FOV encompassing the primary tumor and its
lymphatic drain path (Figure 1). Eight days after inoculation,
the primary tumor was already established, but liver metas-
tases were not visible yet. 3D contrast-enhanced MRI was
used to follow the distribution of intravenously administered
macromolecular contrast material, biotin-BSA-GdDTPA,
over 1 hour. Immediately after administration, the contrast
material was confined to blood vessels (Figure 1B). During
the following hour, the contrast material extravasated from
leaky tumor vessels and gradually accumulated in the tumor
region and in the popliteal lymph node (Figure 1, C–F,
arrows). Apart from enhancing the peritumor region, within
normal tissues the contrast material remained intravascular
(Figure 1, B–F ).
Blood volume fraction (fBV), indicating (micro)vascular
density and permeability surface area product (PS), were
extracted from the 3D dataset by pharmacokinetic analysis
of the accumulation of contrast material (Figure 2, A and B;
see Materials and Methods section). Eb-chk-hpa (n = 19)
and Eb-mock (n = 10) tumors showed both higher blood
volume and higher permeability than the normal surrounding
tissues (higher fBV and PS; Figure 2). The primary tumors
showed no significant difference in either fBV or PS values
between Eb-chk-hpa and Eb-mock. Blood volume and per-
meability were also evaluated for the popliteal lymph node.
Blood volume (fBV) of the popliteal lymph nodes was higher
than the fBV of primary tumors. Both experimental groups
showed similar fBV values of the popliteal lymph node
(Figure 2F ). Vascular permeability of the popliteal lymph
node was significantly increased by heparanase expression;
thus, PS was significantly higher in Eb-chk-hpa tumor-bear-
ing mice relative to the Eb-mock group (Figure 2G; two-tailed
unpaired t test, P = .02).
Histologic Mapping of the Distribution of Contrast Material
The distribution of contrast material was also studied by
histology. Extravasation of fluorescent contrast material
was found in the tumor periphery (Figure 3, A and B,
green). Tracks of invading tumor cells were found in the
periphery of primary Eb tumors (both types) with extrava-
sated contrast material channeled along these tracks
(Figure 3, A and B, arrowheads). In three mice, infiltrating
Eb cells were also found close to the popliteal lymph node
(Figure 3C, arrowheads). Inside the popliteal and subiliac
lymph nodes, contrast material was detected mainly in the
center and perinodal tissues (Figure 3, C–E ). Extravasated
fluorescent MR contrast material was occasionally found
inside draining lymphatics (lumen diameter of approxi-
mately 100 mm) in the normal skin surrounding the tumor
(Figure 3F ). Skin lymphatics were recognized by uptake of
extravasated contrast material (single-stained vessels),
transparency (lack of red blood cells), and typical valve
structures (Figure 3F, arrowheads).
Lymph Node Infiltration by Tumor Cells Preceded
the Formation of Detectable Liver Metastases
Vascular permeability in the popliteal lymph node adja-
cent to primary Eb-chk-hpa tumors was significantly ele-
vated, suggesting invasion of tumor cells into lymph nodes.
Invasion of Eb cells into the normal tissues at the tumor
periphery was detected, but histologic sections showed no
evidence of lymph node metastases (Figures 3 and 4). To
increase the sensitivity of histologic identification of single
infiltrating tumor cells, Eb cells were transfected to express
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EGFP and were detected by immunohistochemistry using
anti-GFP antibodies (Figure 4). Tissue sections taken 8 days
after inoculation of EGFP-expressing Eb cells confirmed the
invasion of tumor cells into the peritumor tissue (Figure 4, A
and B ). Eb cells were found in the rim of the popliteal lymph
node and the subiliac lymph node (Figure 4, C–F ). In
addition, EGFP-expressing Eb cells were found inside blood
vessels and lymphatic vessels (Figure 4, G and H ). At that
time (8 days), as well as 11 days after inoculation, no liver
metastases could be found (Figure 4I ). In contrast, liver
metastases were detected 11 days after inoculation of twice
as many (106) Eb-chk-hpa cells in the lower back (Figure 4J;
as previously reported [2]). At these early time points, the
number of GFP-expressing cells in the lymph nodes was too
low to allow testing the impact of heparanase overexpression
on the infiltration of tumor cells into sentinel lymph nodes.
Spatial Patterns of Peritumor Interstitial Drain
Vascular permeability was determined by the rate of
accumulation of contrast material during the first 15 minutes
postcontrast. However, the leak was continuous, generating
outflow of contrast material from permeable tumor vessels
and toward the peritumor tissue. Consequently, delayed en-
hancement was observed for the peritumor region (Figure 2C).
Color coding the postcontrast time intervals was used to
map this interstitial flow (Time2Max maps; Figure 2, D and
E ). These maps indicate the time of peak in accumulation
rate. Elevated vascular permeability, represented by the first
time interval in the Time2Max map (dark red), usually out-
lined the tumor. Delayed enhancement (accumulation rates
that peak at later time intervals) represented regions in which
enhancement was predominantly due to interstitial convec-
tion rather than vascular leak.
Vascular hyperpermeability will generate a pressure
gradient that subsequently will result in a radial outward
interstitial flow (convection; Time2Max running from dark
red through green to blue) [28]. However, drain of contrast
material in specialized fluid channels rather than (or in
addition to) nonspecific percolation between cells will inter-
rupt this well-ordered convection pattern. Fluorescence mi-
croscopy revealed lymphatic uptake and channeling of
contrast material along invading tumor cells (Figure 3),
supporting the existence and function of draining channels
in the peritumor region. Such channels were, in some cases,
large enough to be resolved also by MRI but required follow-
up of individual slices of the 3D images with time (see
supplementary data).
To trace the dynamic patterns of interstitial flow in the
3D MRI datasets, maps of flow direction were calculated
(Figure 5; see Materials and Methods section). Tumors with
outward convection showed uniform radial distribution of flow
angles surrounding the tumor (Figure 5D), as expected from
simulations (Figure 5C). Delayed enhancement (compare
with Time2Max maps; Figure 5) was detected in some cases
also directed to the tumor core, probably indicating diffusion
of the macromolecular contrast material into the tumor mass.
In some tumors, the radial interstitial convection was dis-
rupted by channels that conveyed faster drain (Figure 5,
E and F ). Channeling of contrast material was detectable
by MRI for 11/19 Eb-chk-hpa and 6/9 Eb-mock tumors.
MRI-detectable peritumor channels associated with the ex-
tent of local invasion of the peritumor tissue, as detected in
histologic sections, and appeared to be independent of
heparanase expression.
Discussion
Heparanase (endoglycosidase) degrades heparan sulfate
proteoglycans in the ECM and blood vessels wall, and thus
it may promote migration and invasion of endothelial and
Figure 3. Extravasation and lymphatic uptake of biotin-BSA-GdDTPA labeled
with fluorescent tag [fluorescein (FAM) or rhodamine (ROX)]. The contrast
material was intravenously injected and allowed to circulate for about 1 hour
(displayed in green). A second probe, fluorescent-tagged BSA (ROX or FAM,
respectively), was injected just before tissue retrieval (displayed in red).
Blood vessels are double-stained (yellow) or more, dominated by the second
probe (orange red). Extravasated contrast material in the interstitial space
and inside lymphatics shows single stain (green). (A–E) Four-micrometer
histologic sections counterstained for nuclei (Hoechst, Molecular Probes,
Inc., Eugene, OR; blue) of tumors (day 8) and adjacent skin tissues (A and B),
popliteal (C and D), and subiliac (E) lymph nodes. Arrowheads indicate
contrast material along Eb cells invading the peritumor skin (A and B) and
infiltrating cells close to the popliteal lymph node (C; merging of two frames).
(F) Confocal microscopy of the inner side of normal skin close to the tumor
(before tissue sectioning for histology; merging of two frames). Arrowheads
indicate valve structures along lymphatic vessels. Scale bar = 200 m.
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cancer cells [1]. In addition, release of heparan sulfate-
bound growth factors [vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF)] from the
ECM contributes to angiogenesis, both in the primary tumor
and at the site of dissemination, resulting in increased
ectopic survival [1]. Nonmetastatic Eb mouse T-lymphoma
cells overexpressing the secreted form of heparanase
acquired increased invasiveness through reconstituted base-
ment membrane and through tissues, manifested by rapid
and massive liver infiltration, with subsequent liver metasta-
ses and dysfunction [2]. Secretion of heparanase stimulated
angiogenesis and vascular maturation in these tumors was
demonstrated by histology and blood oxygenation level–
dependent (BOLD) contrast MRI [2].
We have recently reported that dynamic contrast-
enhanced MRI, using biotin-BSA-GdDTPA, a macromolec-
ular contrast material (a blood pool agent), can be applied for
mapping of vascular permeability, interstitial convection, and
lymphatic drain [28]. Acquisition of 3D gradient echo MRI
allowed sampling of the entire tumor volume and comparison
with the neighboring normal tissues and draining lymph
nodes. As reported here, blood volume fraction (fBV) and
permeability (PS) were elevated in Eb tumors relative to
normal tissues, with no significant difference between hep-
aranase and mock-transfected Eb clones. Heparanase ex-
pression increased vascular permeability in the draining
lymph node; thus, PS was significantly higher in the popliteal
lymph node adjacent to heparanase-expressing tumors rel-
ative to control tumors and resembled PS of the primary
tumor. These results suggest that elevated PS in the lymph
node might be an indication of infiltration or colonization of
tumor cells into the node, resulting in increased vascular
permeability as a consequence of inflammatory reaction or
the release of vascular permeability factors (such as VEGF)
by stroma or tumor cells.
The aim of this work was to determine whether hepar-
anase affects the ability of lymphoma cells to take advantage
of the lymphatic drainage pathway, which normally returns
circulating lymphocytes (and other substances) to the blood
circulation [37]. Histologic evaluation revealed that increased
accumulation of contrast material in draining lymph nodes
was detectable when only a few isolated EGFP-expressing
tumor cells were found in the popliteal and subiliac lymph
nodes, and before establishment of growing lymph node
metastases. Both cell types were capable of lymph node
infiltration, suggesting that Eb cells have an intrinsic ability
to migrate and infiltrate the normal tissues. The intrinsic
heparanase-independent motility of Eb cells was reported
previously by their ability to traverse through collagen type
IV, in contrast to invasion through reconstituted basement
membrane, which was heparanase-dependent [2]. Hepara-
nase expression significantly elevated nodal accumulation of
contrast material, andmight further facilitate colonization and
shorten the time required for the formation of secondary
tumor masses by affecting later stages of metastasis possi-
bly by augmenting the angiogenic capacity of micrometas-
tases. The number of detectable tumor cells within the nodes
was too low at these early stages to allow quantitative
comparison of the impact of heparanase expression on the
number of tumor cells infiltrating the lymph node.
We have previously reported that VEGF-induced hyper-
permeability provides a driving force for the motion of macro-
molecules toward draining lymphatics [28]. Hypothetically,
tumor cells might take advantage of this draining current,
implicating VEGF in lymph node metastasis. Increased
Figure 4. Infiltration of EGFP-expressing Eb lymphoma cells into normal
tissues. (A–H) EGFP-expressing cells were visualized, using anti-GFP
antibody (red) and nuclear counter stain (hematoxylin), in 4-m histologic
sections obtained 8 days after inoculation in the hind limb (0.5  106 cells).
Lymphoma cells were detected in the peritumor tissue (A and B), in the
periphery of the popliteal (C and D) and subiliac (E and F) lymph nodes and
inside blood vessels near the tumor (G; vessel filled with red blood cells), and
lymphatic vessel near the subiliac lymph node (H; vessel lumen devoid of red
blood cells; merging of two frames). (I and J) H&E stain of liver sections
11 days after inoculation of tumor cells in the hind limb (I; 0.5  106 cells; no
metastasis) and in the lower back (J; 1  106 cells; advanced metastasis).
Scale bar = 50 m (A– F, H), 12.5 m (G), 100 m (I and J).
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interstitial flow was recently suggested as the upstream
regulator of lymphangiogenesis [38]. The time frame of our
study (8 days) was significantly shorter than that required for
the formation of new lymphatics in normal skin (weeks)
[38,39]. Therefore, substantial peritumor lymphangiogenesis
was not expected. However, our results suggest that tumor–
host interaction might affect interstitial flow and lymphatic
drain in the peritumor tissue. Highly efficient interstitial
convection may drive macromolecules through the extracel-
lular space without the need for specific channels. Therefore,
Figure 5. Patterns of interstitial convection and flow. (A) Tracking the temporal changes in the direction of the signal intensity gradient (determined in the central
pixel of 3  3 matrices; see Materials and Methods section). Signal intensity gradient in MIP images was assigned magnitude (DSI; white squares) and direction
(black arrows) and then summed for each of six semioverlapping intervals (black squares, gray arrows). (B) The corresponding pixel in the flow map was assigned
the angle obtained at the time interval with the highest-magnitude change (marked by yellow circle in A) color-coded with radial color scale (see below). (C) Flow
analysis was simulated on a model image with inward and outward intensity gradients (indicated by arrows), resulting in a flow map. (D and F) Experimental MR
datasets of three representative mice presented as overlays of MIPs of the first postcontrast time point (1.5 minutes; red) and later time points (after subtraction of
the first time point; green). Arrowheads indicate draining channels. Such MIPs were used for generation of flow maps. Time2Max maps were generated from
concentration maps (see Materials and Methods section). Flow maps varied from almost uniform interstitial convection (D; Eb-chk-hpa) to moderate (E; Eb-chk-
hpa) and massive (F; Eb-mock) channeling of contrast material. Scale bar = 2.5 mm (see also movies in supplementary data).
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when interstitial flow was more effective than lymphatic
drain, it resulted in almost homogeneous radial percolation
flow between the cells. Such outward flux of the contrast
material was also documented around VEGF-overexpress-
ing C6 tumors [28]. However, the radial convection was
disrupted when the drain of contrast material occurred more
efficiently in channels. These channels might be lymphatics
or other fluid channels that might form in the tissue, possi-
bility by loosening of the ECM by the invading tumor cells or
by the fluid current, as a first step in the lymphangiogenic
process [38].
Both increased vascular permeability in the primary tumor
and the presence of tumor cells in the sentinel lymph node
can contribute to lymph node enhancement. As shown here,
lymphatic drain will be manifested in the entire pathway
from the primary tumor toward the lymph node as delayed
enhancement. The early enhancement, during the first
15 minutes after administration of the contrast material,
would be predominantly due to the effect of the tumor cells
on the vasculature in their immediate proximity, and thus
permeability derived for the lymph node might provide a
better direct visualization of tumor cell infiltration.
So far, intravenous MR lymphangiography was done
using USPIO, which, within 24 hours, slowly accumulates in
normal lymph nodes, but is excluded from metastatic nodes
[15]. Gadolinium-based contrast materials were used for in-
terstitial lymphangiography [10–12,17,18]. Here we showed
that dynamic contrast-enhanced MRI using a single intrave-
nous injection of biotin-BSA-GdDTPA-FAM/ROX allowed
detection of angiogenesis, vascular permeability, interstitial
drain, and lymph node involvement. In contrast with USPIO,
in which lymph node involvement is manifested by lack of
contrast accumulation, infiltration of Eb cells into lymph nodes
was manifested by increased accumulation of biotin-BSA-
GdDTPA-FAM/ROX that was enhanced by heparanase ex-
pression. Lymph node infiltration was confirmed by histology
and was shown to precede the formation of liver or lymph
node metastases.
In summary, elevated vascular permeability in the primary
Eb tumors was associated with interstitial convection and
lymphatic drain of the macromolecular contrast material that
was detected by MRI. Early enhancement in the lymph
nodes was induced for those lymph nodes draining the
primary tumors, and enhancement was further elevated for
tumors overexpressing heparanase. These results further
support the role of heparanase in tumor metastasis to
sentinel lymph nodes, as well as the interaction between
vascular permeability, interstitial pressure, and lymphatic
functions, and demonstrate the ability to track these inter-
actions by contrast-enhanced MRI.
References
[1] Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z,
Elkin M, Peretz T, and Friedmann Y (2002). Mammalian heparanase:
involvement in cancer metastasis, angiogenesis and normal develop-
ment. Semin Cancer Biol 12, 121–129.
[2] Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H,
Friedmann Y, Schirrmacher V, Mitrani E, and Vlodavsky I (2002). Cell
surface expression and secretion of heparanase markedly promote
tumor angiogenesis and metastasis. Proc Natl Acad Sci USA 99,
10031–10036.
[3] Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, and Parish
CR (1999). Cloning of mammalian heparanase, an important enzyme in
tumor invasion and metastasis. Nat Med 5, 803–809.
[4] Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, and Nicolson GL
(1983). Heparan sulfate degradation: relation to tumor invasive and
metastatic properties of mouse B16 melanoma sublines. Science
220, 611–613.
[5] Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, and
Pappo O (2000). Expression of heparanase in normal, dysplastic, and
neoplastic human colonic mucosa and stroma. Evidence for its role in
colonic tumorigenesis. Am J Pathol 157, 1167–1175.
[6] Papoutsi M, Siemeister G, Weindel K, Tomarev SI, Kurz H, Schachtele
C, Martiny-Baron G, Christ B, Marme D, and Wilting J (2000). Active
interaction of human A375 melanoma cells with the lymphatics in vivo.
Histochem Cell Biol 114, 373–385.
[7] He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi
T, and Alitalo K (2002). Suppression of tumor lymphangiogenesis and
lymph node metastasis by blocking vascular endothelial growth factor
receptor 3 signaling. J Natl Cancer Inst 94, 819–825.
[8] Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo
R, Jackson DG, Nishikawa Si S, Kubo H, and Achen MG (2001).
VEGF-D promotes the metastatic spread of tumor cells via the lym-
phatics. Nat Med 7, 186–191.
[9] Alazraki NP, Styblo T, Grant SF, Cohen C, Larsen T, and Aarsvold JN
(2000). Sentinel node staging of early breast cancer using lymphoscin-
tigraphy and the intraoperative gamma-detecting probe. Semin Nucl
Med 30, 56–64.
[10] Shimada M, Yoshikawa K, Suganuma T, Kayanuma H, Inoue Y, Ito K,
Senoo A, and Hayashi S (2003). Interstitial magnetic resonance lym-
phography: comparative animal study of gadofluorine 8 and gadolinium
diethylenetriamine-pentaacetic acid. J Comput Assist Tomogr 27,
641–646.
[11] Ruehm SG, Corot C, and Debatin JF (2001). Interstitial MR lympho-
graphy with a conventional extracellular gadolinium-based agent:
assessment in rabbits. Radiology 218, 664–669.
[12] Herborn CU, Lauenstein TC, Vogt FM, Lauffer RB, Debatin JF, and
Ruehm SG (2002). Interstitial MR lymphography with MS-325: charac-
terization of normal and tumor-invaded lymph nodes in a rabbit model.
AJR Am J Roentgenol 179, 1567–1572.
[13] Anzai Y and Prince MR (1997). Iron oxide–enhanced MR lymphogra-
phy: the evaluation of cervical lymph node metastases in head and
neck cancer. J Magn Reson Imaging 7, 75–81.
[14] Kobayashi H, Kawamoto S, Sakai Y, Choyke PL, Star RA, Brechbiel
MW, Sato N, Tagaya Y, Morris JC, and Waldmann TA (2004). Lym-
phatic drainage imaging of breast cancer in mice by micro-magnetic
resonance lymphangiography using a nano-size paramagnetic contrast
agent. J Natl Cancer Inst 96, 703–708.
[15] Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, and
Josephson L (1990). Ultrasmall superparamagnetic iron oxide: charac-
terization of a new class of contrast agents for MR imaging. Radiology
175, 489–493.
[16] Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S,
van de Kaa CH, de la Rosette J, and Weissleder R (2003). Noninvasive
detection of clinically occult lymph-node metastases in prostate cancer.
N Engl J Med 348, 2491–2499.
[17] McCauley TR, Rifkin MD, and Ledet CA (2002). Pelvic lymph node
visualization with MR imaging using local administration of ultra-small
superparamagnetic iron oxide contrast. J Magn Reson Imaging 15,
492–497.
[18] Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA,
Waldmann TA, Tagaya Y, and Brechbiel MW (2003). Comparison
of dendrimer-based macromolecular contrast agents for dynamic
micro-magnetic resonance lymphangiography. Magn Reson Med 50,
758–766.
[19] Daldrup-Link HE and Brasch RC (2003). Macromolecular contrast
agents for MR mammography: current status. Eur Radiol 13,
354–365 Epub 2002 October 2031.
[20] Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, and
Brasch RC (1987). Albumin labeled with Gd-DTPA. An intravascular
contrast-enhancing agent for magnetic resonance blood pool imaging:
preparation and characterization. Invest Radiol 22, 665–671.
[21] Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, Ferrara N,
Cohen RL, and Brasch RC (1998). Magnetic resonance imaging
detects suppression of tumor vascular permeability after administration
232 MRI Detection of Lymphatic Dissemination Dafni et al.
Neoplasia . Vol. 7, No. 3, 2005
of antibody to vascular endothelial growth factor. Cancer Invest 16,
225–230.
[22] Marzola P, Farace P, Calderan L, Crescimanno C, Lunati E, Nicolato
E, Benati D, Degrassi A, Terron A, Klapwijk J, Pesenti E, Sbarbati A,
and Osculati F (2003). In vivo mapping of fractional plasma volume
(fpv) and endothelial transfer coefficient (Kps) in solid tumors using a
macromolecular contrast agent: correlation with histology and ultra-
structure. Int J Cancer 104, 462–468.
[23] Wang Z, Su MY, Najafi A, and Nalcioglu O (2001). Effect of vasodilator
hydralazine on tumor microvascular random flow and blood volume as
measured by intravoxel incoherent motion (IVIM) weighted MRI in con-
junction with Gd-DTPA-Albumin enhanced MRI. Magn Reson Imaging
19, 1063–1072.
[24] Bhujwalla MZ, Artemov D, Natarajan K, Solaiyappan M, Kollars P, and
Kristjansen PE (2003). Reduction of vascular and permeable regions in
solid tumors detected by macromolecular contrast magnetic resonance
imaging after treatment with antiangiogenic agent TNP-470. Clin Can-
cer Res 9, 355–362.
[25] Shames DM, Kuwatsuru R, Vexler V, Muhler A, and Brasch RC (1993).
Measurement of capillary permeability to macromolecules by dynamic
magnetic resonance imaging: a quantitative noninvasive technique.
Magn Reson Med 29, 616–622.
[26] van Dijke CF, Brasch RC, Roberts TP, Weidner N, Mathur A, Shames
DM, Mann JS, Demsar F, Lang P, and Schwickert HC (1996). Mam-
mary carcinoma model: correlation of macromolecular contrast-
enhanced MR imaging characterizations of tumor microvasculature
and histologic capillary density. Radiology 198, 813–818.
[27] Saeed M, van Dijke CF, Mann JS, Wendland MF, Rosenau W,
Higgins CB, and Brasch RC (1998). Histologic confirmation of micro-
vascular hyperpermeability to macromolecular MR contrast
medium in reperfused myocardial infarction. J Magn Reson Imaging
8, 561–567.
[28] Dafni H, Israely T, Bhujwalla ZM, Benjamin LE, and Neeman M (2002).
Overexpression of vascular endothelial growth factor 165 drives peri-
tumor interstitial convection and induces lymphatic drain: magnetic res-
onance imaging, confocal microscopy, and histological tracking of
triple-labeled albumin. Cancer Res 62, 6731–6739.
[29] Dafni H, Landsman L, Schechter B, Kohen F, and Neeman M (2002).
MRI and fluorescence microscopy of the acute vascular response
to VEGF165: vasodilation, hyper-permeability and lymphatic uptake,
followed by rapid inactivation of the growth factor. NMR Biomed 15,
120–131.
[30] Dafni H, Gilead A, Nevo N, Eilam R, Harmelin A, and Neeman M
(2003). Modulation of the pharmacokinetics of macromolecular contrast
material by avidin chase: MRI, optical, and inductively coupled plasma
mass spectrometry tracking of triply labeled albumin. Magn Reson Med
50, 904–914.
[31] Israely T, Dafni H, Granot D, Nevo N, Tsafriri A, and Neeman M (2003).
Vascular remodeling and angiogenesis in ectopic ovarian transplants:
a crucial role of pericytes and vascular smooth muscle cells in main-
tenance of ovarian grafts. Biol Reprod 68, 2055–2064 Epub 2003
January 2022.
[32] Neeman M and Dafni H (2003). Structural, functional, and molecular
MR imaging of the microvasculature. Annu Rev Biomed Eng 5, 29–56.
[33] Ziv K, Nevo N, Dafni H, Israely T, Granot D, Brenner O, and Neeman M
(2004). Longitudinal MRI tracking of the angiogenic response to hind
limb ischemic injury in the mouse. Magn Reson Med 51, 304–311.
[34] Goldshmidt O, Zcharia E, Aingorn H, Guatta-Rangini Z, Atzmon R,
Michal I, Pecker I, Mitrani E, and Vlodavsky I (2001). Expression pat-
tern and secretion of human and chicken heparanase are determined
by their signal peptide sequence. J Biol Chem 276, 29178–29187.
[35] Vlodavsky I (1999). Preparation of extracellular matrices produced
by cultured corneal endothelial and PF-HR9 endodermal cells. Current
Protocols in Cell Biology, pp. 10.14.11–10.14.14 John Wiley & Sons
Inc., Hoboken, NJ.
[36] Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, and Schirrmacher V (1983).
Lymphoma cell –mediated degradation of sulfated proteoglycans in the
subendothelial extracellular matrix: relationship to tumor cell metasta-
sis. Cancer Res 43, 2704–2711.
[37] Witte MH,Way DL, Witte CL, and Bernas M (1997). Lymphangiogenesis:
mechanisms, significance and clinical implications. In Goldberg, EM,
Rosen, EM (Eds.), Regulation of Angiogenesis, Vol. 79, pp. 65–112
Birkhauser Verlag, Basel.
[38] Boardman KC and Swartz MA (2003). Interstitial flow as a guide for
lymphangiogenesis. Circ Res 92, 801–808.
[39] Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts
JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, and Dvorak HF
(2002). Vascular permeability factor/vascular endothelial growth factor
induces lymphangiogenesis as well as angiogenesis. J Exp Med 196,
1497–1506.
MRI Detection of Lymphatic Dissemination Dafni et al. 233
Neoplasia . Vol. 7, No. 3, 2005
